TCRR Insider Trading Activity and SEC Form 4 Filings
TCRR insider trading summary
No open-market insider purchases or sales of Tcr2 Therapeutics Inc. (TCRR) have been reported on SEC Form 4 in the past 12 months.
Latest TCRR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 25, 2023 | Tang Capital Partners LP | 10% Owner | Buy | $86K (50,000 @ $1.72) |
| May 25, 2023 | Kevin C Tang | 10% Owner | Buy | $86K (50,000 @ $1.72) |
| May 25, 2023 | Tang Capital Management LLC | 10% Owner | Buy | $86K (50,000 @ $1.72) |
| May 22, 2023 | Luke Evnin | 10% Owner | Sell | $132K (70,170 @ $1.88) |
| May 22, 2023 | Ansbert Gadicke | Director | Sell | $132K (70,170 @ $1.88) |
| May 22, 2023 | Mpm Asset Management LLC | 10% Owner | Sell | $132K (70,170 @ $1.88) |
| May 12, 2023 | Kevin C Tang | 10% Owner | Buy | $12K (6,183 @ $1.95) |
| May 12, 2023 | Tang Capital Partners LP | 10% Owner | Buy | $12K (6,183 @ $1.95) |
| May 12, 2023 | Tang Capital Management LLC | 10% Owner | Buy | $12K (6,183 @ $1.95) |
| May 11, 2023 | Kevin C Tang | 10% Owner | Buy | $76K (38,765 @ $1.95) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.